PROFOUND MEDICAL CORP (PRN.CA) Stock Price, Quote, News and Overview
TSX:PRN - Toronto Stock Exchange - CA74319B5027 - Common Stock - Currency: CAD
PRN.CA Quote, Performance and Key Statistics
TSX:PRN (3/7/2025, 7:00:00 PM)
9.91
-0.43 (-4.16%)
The current stock price of PRN.CA is 9.91 CAD. In the past month the price increased by 11.98%. In the past year, price decreased by -9%.
PRN.CA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| MIR.CA | MEDMIRA INC | N/A | 79.62M | ||
| TLT.CA | THERALASE TECHNOLOGIES INC | N/A | 61.95M | ||
| PINK.CA | PERIMETER MEDICAL IMAGING AI | N/A | 50.50M | ||
| NSCI.CA | NANALYSIS SCIENTIFIC CORP | N/A | 33.97M | ||
| CNVI.CA | CONAVI MEDICAL CORP | N/A | 28.76M | ||
| VPT.CA | VENTRIPOINT DIAGNOSTICS LTD | N/A | 27.68M | ||
| ASG.CA | AURORA SPINE CORP | N/A | 24.90M | ||
| MDX.CA | MEDX HEALTH CORP | N/A | 17.70M | ||
| THRM.CA | THERMA BRIGHT INC | N/A | 15.91M | ||
| EVMT.CA | EVOME MEDICAL TECHNOLOGIES I | N/A | 4.81M |
Related stock screener links
About PRN.CA
Company Profile
Profound Medical Corp. engages in developing, manufacturing, and marketing of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 131 full-time employees. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Company Info
PROFOUND MEDICAL CORP
2400 Skymark Ave Unit 6
Mississauga ONTARIO L4W 5K5 CA
CEO: Arun Menawat
Employees: 131
Company Website: https://profoundmedical.com/
Investor Relations: https://profoundmedical.com/investors/
Phone: 16474761350
PROFOUND MEDICAL CORP / PRN.CA FAQ
What is the stock price of PROFOUND MEDICAL CORP today?
The current stock price of PRN.CA is 9.91 CAD. The price decreased by -4.16% in the last trading session.
What is the ticker symbol for PROFOUND MEDICAL CORP stock?
The exchange symbol of PROFOUND MEDICAL CORP is PRN and it is listed on the Toronto Stock Exchange exchange.
On which exchange is PRN.CA stock listed?
PRN.CA stock is listed on the Toronto Stock Exchange exchange.
What is the price forecast or stock price prediction for PROFOUND MEDICAL CORP stock?
6 analysts have analysed PRN.CA and the average price target is 24.91 CAD. This implies a price increase of 151.35% is expected in the next year compared to the current price of 9.91. Check the PROFOUND MEDICAL CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROFOUND MEDICAL CORP worth?
PROFOUND MEDICAL CORP (PRN.CA) has a market capitalization of 297.70M CAD. This makes PRN.CA a Micro Cap stock.
How many employees does PROFOUND MEDICAL CORP have?
PROFOUND MEDICAL CORP (PRN.CA) currently has 131 employees.
What are the support and resistance levels for PROFOUND MEDICAL CORP (PRN.CA) stock?
PROFOUND MEDICAL CORP (PRN.CA) has a support level at 9.88 and a resistance level at 10.04. Check the full technical report for a detailed analysis of PRN.CA support and resistance levels.
Is PROFOUND MEDICAL CORP (PRN.CA) expected to grow?
The Revenue of PROFOUND MEDICAL CORP (PRN.CA) is expected to grow by 151.33% in the next year. Check the estimates tab for more information on the PRN.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PROFOUND MEDICAL CORP (PRN.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRN.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRN.CA, evaluating the profitability, health, valuation and growth aspects
- PROFOUND MEDICAL CORP (PRN.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROFOUND MEDICAL CORP (PRN.CA) Sales and EPS estimates to see what analysts future expectations are.
- PROFOUND MEDICAL CORP (PRN.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROFOUND MEDICAL CORP (PRN.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROFOUND MEDICAL CORP (PRN.CA) Stock Chart to make your own analysis
- PROFOUND MEDICAL CORP (PRN.CA) Latest news and press-releases to stay up to date.
Does PROFOUND MEDICAL CORP (PRN.CA) stock pay dividends?
PRN.CA does not pay a dividend.
When does PROFOUND MEDICAL CORP (PRN.CA) report earnings?
PROFOUND MEDICAL CORP (PRN.CA) will report earnings on 2025-05-07, after the market close.
What is the Price/Earnings (PE) ratio of PROFOUND MEDICAL CORP (PRN.CA)?
PROFOUND MEDICAL CORP (PRN.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.61).
PRN.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PRN.CA. When comparing the yearly performance of all stocks, PRN.CA is a bad performer in the overall market: 74.57% of all stocks are doing better.
PRN.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRN.CA. PRN.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PRN.CA Financial Highlights
Over the last trailing twelve months PRN.CA reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS increased by 17.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.32% | ||
| ROE | -101.05% | ||
| Debt/Equity | 0.12 |
PRN.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PRN.CA. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 19.06% and a revenue growth 151.33% for PRN.CA